mdlinx mdlinx

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.


* From Email: 
* To Email: 
To Email: 
To Email: 
To Email: 
To Email: 
Email Subject Line: 
Comments:

Chemotherapy within 30 days before surgery does not augment postoperative mortality and morbidity

Turan A et al. – Preoperative use of neoadjuvant chemotherapy in cancer patients undergoing resection surgeries was not associated with a higher rate of early postoperative complications or mortality.

Methods
  • The authors evaluated 971,455 patients from the American College of Surgeons National Surgical Quality Improvement Program database.
  • Patients were defined as having chemotherapy when they were given any chemotherapy for malignancy within 30 days before surgery.
  • They successfully matched 1,348 pairs of chemotherapy recipients and non–recipients.

Results
  • Twenty–one of the 1,348 (1.6%) non–chemotherapy patients died within 30days after surgery compared with 30 of the 1,348 (2.2%) chemotherapy patients.
  • Twenty–one of the 1,348 (1.6%) non–chemotherapy patients died within 30days after surgery compared with 30 of the 1,348 (2.2%) chemotherapy patients.
  • The most common complication observed was wound infection in 13.1% of non–chemotherapy patients compared with 14.2% of the chemotherapy patients.
  • There was similarly no difference between groups for the collapsed composite of major morbidities [OR=1.17; 95% CI 0.97 to 1.42; P=0.09].
[more...]

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close